Marc Olivier Perret
Directeur Général chez Gilde Healthcare Holding BV
Profil
Marc Olivier Perret is currently the Co-Managing Director at Gilde Healthcare Holding BV.
He is also the Managing Partner at Gilde Healthcare Partners BV and the General Partner at Coöperatieve Gilde Healthcare II UA.
Previously, he served as an Independent Director at Conatus Pharmaceuticals, Inc. from 2006 to 2013.
He was also a Director at Neuro3D SA, Innate Pharma SA, CropDesign NV, BioProtein Technologies SA, and Head-Mergers & Acquisitions at Novartis Corp.
Mr. Perret obtained his undergraduate degree from Ecole Centrale Lyon.
Postes actifs de Marc Olivier Perret
| Sociétés | Poste | Début |
|---|---|---|
Gilde Healthcare Partners BV
 Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Private Equity Investor | 01/10/2000 |
| Coöperatieve Gilde Healthcare II UA | Corporate Officer/Principal | - |
Gilde Healthcare Holding BV
 Gilde Healthcare Holding BV Financial ConglomeratesFinance Gilde Healthcare Holding BV is an investment holding Dutch company. The private company is based in Utrecht, NL. and has subsidiaries in Australia, Netherlands, United States and Germany. The CEOs of the company are Edwin William de Graaf, Marc Olivier Perret. | Directeur Général | - |
Anciens postes connus de Marc Olivier Perret
| Sociétés | Poste | Fin |
|---|---|---|
| HISTOGEN INC. | Directeur/Membre du Conseil | 31/12/2013 |
BioProtein Technologies SA
 BioProtein Technologies SA BiotechnologyHealth Technology BioProtein Technologies SA develops recombinant therapeutic proteins and vaccines. Its proprietary technology offers customized packages supplying highly purified biopharmaceuticals. The firm provides pharmaceutical and biotechnology companies with integrated services from gene expression to industrial production of proteins and vaccines in milk. The company was founded on July 1, 1988 by Marc Le Bozec, Louis-Marie Houdebine, Jean-Paul Renard, Bernard Jégou and François Deneux and is headquartered in Jouy-en-Josas, France. | Directeur/Membre du Conseil | 20/12/2013 |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Neuro3D SA
 Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Directeur/Membre du Conseil | - |
| INNATE PHARMA | Directeur/Membre du Conseil | - |
Formation de Marc Olivier Perret
| Ecole Centrale Lyon | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INNATE PHARMA | Health Technology |
| Entreprise privées | 8 |
|---|---|
BioProtein Technologies SA
BioProtein Technologies SA BiotechnologyHealth Technology BioProtein Technologies SA develops recombinant therapeutic proteins and vaccines. Its proprietary technology offers customized packages supplying highly purified biopharmaceuticals. The firm provides pharmaceutical and biotechnology companies with integrated services from gene expression to industrial production of proteins and vaccines in milk. The company was founded on July 1, 1988 by Marc Le Bozec, Louis-Marie Houdebine, Jean-Paul Renard, Bernard Jégou and François Deneux and is headquartered in Jouy-en-Josas, France. | Health Technology |
Conatus Pharmaceuticals, Inc.
 Conatus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA. | Health Technology |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Commercial Services |
Neuro3D SA
Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Health Technology |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Finance |
| Coöperatieve Gilde Healthcare II UA | Finance |
Gilde Healthcare Holding BV
Gilde Healthcare Holding BV Financial ConglomeratesFinance Gilde Healthcare Holding BV is an investment holding Dutch company. The private company is based in Utrecht, NL. and has subsidiaries in Australia, Netherlands, United States and Germany. The CEOs of the company are Edwin William de Graaf, Marc Olivier Perret. | Finance |
